Lilly reports mixed data for Cyramza in first-line gastric cancer

Eli Lilly and Co. (NYSE:LLY) reported top-line data from the Phase III RAINFALL trial in 645 patients with HER2-negative metastatic gastric

Read the full 214 word article

User Sign In